What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination

European Journal of Cancer

Volumn 45, Issue 15, 2009, Pages 2714-2721

  Lynge, Elsebeth ^a   Antilla, Ahti ^b   Arbyn, Marc ^c   Segnan, Nereo ^d   Ronco, Guglielmo ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FINNISH CANCER REGISTRY   (Finland)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^d CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

Author keywords

Cervical; Europe; Screening

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ARTICLE; CANCER GRADING; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CONDOM; CYTOLOGY; EUROPE; HEALTH CARE POLICY; HUMAN; LONG TERM CARE; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS; WART VIRUS;

ADOLESCENT; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYTOLOGICAL TECHNIQUES; EUROPE; FEMALE; FORECASTING; HEALTH POLICY; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 70349189337     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.07.024     Document Type: Article

References (49)

1. Arbyn M, Antilla A, Jordan J, et al., editors. European guidelines for quality assurance in cervical cancer screening. Luxembourg: European Commission; 2008.
2. Anttila A., von Karsa L., Aasmaa A., et al. Cervical cancer screening policies and coverage in Europe. Eur J Cancer 45 15 (2009) 2629-2631
3. Arbyn M., Rebojl M., de Kok I.M., Becker N., O'Reilly M., and Andrea B. The challenges of organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer 45 15 (2009) 2671-2678
4. Parkin D.M., and Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 24S3 (2006) 11-25
5. [accessed 11.07.08].
6. McCredie M.R., Sharples K.J., Paul C., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9 (2008) 425-434
7. Schwartz E., Freese U.K., Gissmann L., et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314 (1985) 111-114
8. Muñoz N., Bosch F.X., de Sanjosé S., et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 52 (1992) 743-749
9. Bosch F.X., Manos M.M., Muñoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 87 (1995) 796-802
10. International Agency for Research on Cancer. IARC monograph on the evaluation of carcinogenic risks to humans. Human papillomaviruses, vol. 64. International Agency for Research on Cancer: Lyon, France; 1995.
11. International Agency for Research on Cancer. IARC monograph on the evaluation of carcinogenic risks to humans. Human papillomaviruses, vol. 90. International Agency for Research on Cancer: Lyon, France; 2007.
12. De Vuyst H., Clifford G., Li N., and Franceschi S. HPV infection in Europe. Eur J Cancer 45 15 (2009) 2632-2639
13. Manhart L.E., and Koutsky L.A. Do condoms prevent genital HPV infection, external genital warts, or cervical cancer? A meta-analysis. Sex Transm Dis 29 (2002) 725-735
14. Winer R.L., Hughes J.P., Feng Q., et al. Condom use and the risk of genital human papillomavirus infection in young women. N Eng J Med 354 (2006) 2645-2654
15. Hogewoning C.J.A., Bleeker M.C.G., van der Brule A.J.C., et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomised clinical trial. Int J Cancer 107 (2003) 811-816
16. Anonymous. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. IARC Working Group on evaluation of cervical cancer screening programmes. BMJ 293 (1986) 659-664
17. Solomon D., Davey D., Kurman R., et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287 (2002) 2114-2119
18. Arbyn M., Bergeron C., Klinkhamer P., Martin-Hirsch P., Siebers A.G., and Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 111 (2008) 167-177
19. Davey E., d'Asuncao J., Irwing L., et al. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ 335 (2007) 31-34
20. Cuzick J., Arbyn M., Sankaranarayanan R., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26S (2008) K29-K41
21. Meijer C.J., Berkhof J., Castle P.E., et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124 (2009) 516-520
22. Arbyn M., Buntinx F., van Ranst M., Paraskevaidis E., Martin-Hirsch P., and Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasm. J Natl Cancer Inst 96 (2004) 280-293
23. Ronco G., Cuzick J., Segnan N., et al. HPV triage for Low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. Eur J Cancer 43 (2007) 476-480
24. Szarewski A., Ambroisine L., Cadman L., et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 17 (2008) 3033-3042
25. Koliopoulos G., Arbyn M., Martin-Hirsch P., Kyrgiou M., Prendiville W., and Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomised studies. Gynecol Oncol 104 (2007) 232-246
26. Dillner J., Rebolj M., Birembaut P., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337 (2008) a1754 10.1136/bmj.a175
27. Mayrand M.H., Duarte-Franco E., Rodrigues I., et al. Human papillomavirus DNA versus Papanicolau screening tests for cervical cancer. New Engl J Med 357 (2007) 1579-1588
28. Davies P., Arbyn M., Dillner J., et al. A report on the status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int J Cancer 118 (2006) 791-796
29. Naucler P., Ryd W., Törnberg S., et al. Human papillomavirus and papanicolaou tests to screen for cervical cancer. N Eng J Med 357 (2007) 1589-1597
30. Bulkmans NWJ, Berkhof J, Rozendall L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007. doi:10,1916/S0140-6736(07)61450-0.
31. Ronco G., Giorgi-Rossi P., Corozzi F., et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 7 (2006) 547-555
32. Ronco G., Segnan N., Giorgi-Rossi P., et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from a new technologies for cervical cancer randomised controlled trial. J Natl Cancer Inst 98 (2006) 765-774
33. Kotaniemi-Talonen L., Anttila A., Malila N., et al. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 44 (2008) 565-571
34. Ronco G., Giorgi-Rossi P., Carozzi F., et al. Results at recruitment from a randomised controlled trial comparing human papillomavirus testing alone with conventional cytology as a primary cervical cancer screening test. J Natl Cancer Inst 100 (2008) 492-501
35. Garland S.M., Hermandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Eng J Med 356 (2007) 1928-1943
36. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Eng J Med 356 (2007) 1915-1927
37. Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccinbe against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
38. Lévy-Bruhl D., King L.A., O' Flanagan D., et al. State of introduction of HPV vaccination into national immunisation schedules in Europe: results of the VENICE* 2008 survey. Eur J Cancer 45 15 (2009) 2709-2713
39. Lund E., and Bjerkedal T. Cancer cervicis uteri in situ. Increased perinatal mortality and prematurity after conisation. Tidskr Nor Lægeforen 106 (1986) 543-546 in Norwegian
40. Kristensen J., Langhoof-Ross J., and Kristensen F.B. Increased risk of preterm birth in women with cervical conization. Obstet Gynecol 81 (1993) 1005-1008
41. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prenville W., and Paraskevaidis E. Obstectric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367 (2006) 489-498
42. Arbyn M., Kyrgiou M., Simoens C., et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 337 (2008) a1284 10.1136/bmj.a128
43. Kalliala I., Anttila A., Pukkala E., and Nieminen P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ 331 (2005) 1183-1185
44. Kiviat N.B., Hawes S.E., and Feng Q. Screening for cervical cancer in the era of the HPV vaccine -the urgent need for both new screening guidelines and new biomarkers. J Natl Cancer Inst 100 (2008) 290-291
45. European Centre for Disease Prevention and Control. Guidance for the introduction of HPV vaccines in the EU countries. Stockholm: ECDC; 2008.
46. Franco E.L., and Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 26 Suppl 1 (2008) A16-A23
47. Ronco G., and Giorgi-Rossi P. New paradigms in cervical cancer prevention: opportunities and risks. BMC Women's Health 8 (2008) 23
48. Khan M.J., Castle P.E., Lorincz A.T., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97 (2005) 1072-1079
49. Dalla Palma P., Giorgi-Rossi P., Collina G., et al. The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histological lesions found in the NTCC trial. Am J Clin Pathol 129 (2008) 75-80